KRAS and cancer: Because RMC-6236 targets the active, GTP-bound form of RAS proteins, we hypothesized that RMC-6236 may be more active in cancer cells with KRAS-mutant allele copy-number gain than those inhibitors targeting the GDP-bound form of RAS proteins.